{"id":"measles-vaccine-mv","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Fever"},{"rate":"5","effect":"Rash"},{"rate":"20-30","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"1-2","effect":"Lymphadenopathy"},{"rate":null,"effect":"Thrombocytopenia (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live attenuated (weakened) measles virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize wild-type measles virus upon exposure, providing long-lasting protection against measles infection.","oneSentence":"The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:16.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles in children and adults"},{"name":"Post-exposure prophylaxis in unvaccinated or susceptible individuals"}]},"trialDetails":[{"nctId":"NCT01306006","phase":"PHASE4","title":"The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2011-02","conditions":"Mortality, Vaccines","enrollment":3500},{"nctId":"NCT04521764","phase":"PHASE1","title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-09-23","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma","enrollment":54},{"nctId":"NCT04055454","phase":"PHASE1","title":"A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2019-09-26","conditions":"Lassa Virus Infection","enrollment":60},{"nctId":"NCT02700230","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-03-22","conditions":"Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor","enrollment":9},{"nctId":"NCT03460002","phase":"PHASE4","title":"Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2016-11","conditions":"Measles Vaccination, Oral Polio Vaccine, Non-specific/Heterologous Effects of Vaccines","enrollment":28612},{"nctId":"NCT02943681","phase":"NA","title":"A Second Dose of Measles Vaccine (MV) in the Second Year of Life","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2016-10","conditions":"Child Mortality, Child Morbidity","enrollment":3812},{"nctId":"NCT03807843","phase":"PHASE2","title":"Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2019-07-16","conditions":"Chikungunya Virus Infection","enrollment":41},{"nctId":"NCT02861586","phase":"PHASE2","title":"Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2016-08-17","conditions":"Chikungunya Virus Infection","enrollment":263},{"nctId":"NCT03635086","phase":"PHASE2","title":"Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2018-08-22","conditions":"Chikungunya Virus Infection","enrollment":60},{"nctId":"NCT03101111","phase":"PHASE2","title":"Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2017-08-09","conditions":"Chikungunya","enrollment":34},{"nctId":"NCT03028441","phase":"PHASE1","title":"Phase I Trial of Measles Vectored Chikungungya Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-05-30","conditions":"Chikungunya Virus Infection","enrollment":180},{"nctId":"NCT00249769","phase":"PHASE3","title":"Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2005-11-21","conditions":"Encephalitis, Japanese B","enrollment":600},{"nctId":"NCT00450814","phase":"PHASE1, PHASE2","title":"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-11-30","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":48},{"nctId":"NCT02710045","phase":"NA","title":"The Interaction Between Measles and DTP Vaccination","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2007-11","conditions":"Non-target Heterologous Effects of Vaccines, Vaccine Interactions","enrollment":302},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT02333474","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Lung Neoplasms","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":645,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Measles Vaccine (MV)","genericName":"Measles Vaccine (MV)","companyName":"PATH","companyId":"path","modality":"Biologic","firstApprovalDate":"","aiSummary":"The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease. Used for Prevention of measles in children and adults, Post-exposure prophylaxis in unvaccinated or susceptible individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}